Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000516362 | SCV000614171 | uncertain significance | not specified | 2017-01-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000703154 | SCV000832040 | benign | Nemaline myopathy 2 | 2024-01-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002527496 | SCV003710699 | uncertain significance | Inborn genetic diseases | 2022-03-21 | criteria provided, single submitter | clinical testing | The c.18274A>C (p.M6092L) alteration is located in exon 135 (coding exon 133) of the NEB gene. This alteration results from a A to C substitution at nucleotide position 18274, causing the methionine (M) at amino acid position 6092 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV003133299 | SCV003811561 | likely benign | not provided | 2023-06-28 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000703154 | SCV001456466 | uncertain significance | Nemaline myopathy 2 | 2020-01-09 | no assertion criteria provided | clinical testing |